Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Tradegate
24.04.25
11:05 Uhr
12,090 Euro
+0,185
+1,55 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,95012,14511:56
12,10512,24011:56

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.04.Viridian Therapeutics appoints Jeff Ajer to board1
VIRIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln
07.04.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
04.04.Stifel maintains Buy on Viridian Therapeutics, $41 target2
11.03.Viridian Therapeutics Announces Inducement Stock Option Grants1
10.03.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
03.03.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Viridian Therapeutics, Inc.\DE - 10-K, Annual Report-
27.02.Viridian Therapeutics GAAP EPS of -$0.81 beats by $0.24, revenue of $0.07M beats by $0.02M2
27.02.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
10.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.01.Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts1
17.12.24Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views1
16.12.24Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease39
16.12.24Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
12.11.24Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data228WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
28.10.24Needham maintains buy on VRDN shares, cites recent clinical trial results4
28.10.24Analyst Expectations For Viridian Therapeutics' Future5
08.08.24Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results168WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
08.05.24Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results178WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1